Verrica CEO granted 512,269 stock options

Verrica Pharmaceuticals CEO and President Jayson Rieger was granted an employee stock option covering 512,269 shares of common stock at an exercise price of $8.21 per share.

Rhea-AI Filing Summary

Verrica Pharmaceuticals CEO and President Jayson Rieger was granted an employee stock option covering 512,269 shares of common stock at an exercise price of $8.21 per share. The option expires on December 23, 2035 and vests in two tranches tied to share-price hurdles.

Half of the option vests if Verrica’s Nasdaq closing price reaches at least $15.00 per share, and the other half vests if it reaches at least $25.00 per share, in each case subject to his continued service. The grant was originally approved in December 2025 and became effective after shareholders approved an amendment to the 2018 Equity Incentive Plan on June 5, 2026.

Insider Trade Summary

Grant/Award: 512,269 shares

Grant/Award 1 txn

Insider Rieger Jayson

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	512,269	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 512,269 contracts (Direct)

Footnotes (2)

1. F1. The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.
2. F2. 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

Option grant size: 512,269 shares Exercise price: $8.21 per share Expiration date: December 23, 2035 +3 more

6 metrics

Option grant size 512,269 shares Employee stock option granted to CEO

Exercise price $8.21 per share Strike price of granted option

Expiration date December 23, 2035 Option term end

Post-grant derivative holdings 512,269 derivatives Total options held after transaction

First vesting hurdle $15.00 share price 50% of option vests at this Nasdaq close

Second vesting hurdle $25.00 share price Remaining 50% vests at this Nasdaq close

Key Terms

Employee Stock Option, 2018 Equity Incentive Plan, vesting, closing sales price

4 terms

Employee Stock Option financial

"security_title: Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

2018 Equity Incentive Plan financial

"amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted"

vesting financial

"50% of the total shares subject to the option shall vest on the date that the closing sales price per share"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

closing sales price financial

"on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Verrica Pharmaceuticals (VRCA) CEO Jayson Rieger report in this Form 4?

Jayson Rieger reported receiving an employee stock option for 512,269 shares of Verrica common stock at a $8.21 exercise price. The option is compensation, not an open-market trade, and is subject to specific stock-price vesting conditions and continued service requirements.

What are the key terms of Jayson Rieger’s new Verrica (VRCA) stock option?

The option covers 512,269 shares at a fixed exercise price of $8.21 per share and expires on December 23, 2035. It was granted under Verrica’s 2018 Equity Incentive Plan, following shareholder approval of an amendment on June 5, 2026.

How does the vesting of the Verrica (VRCA) CEO’s stock option work?

Vesting is based on Verrica’s share price. 50% of the option vests once the Nasdaq closing price reaches at least $15.00 per share, and the remaining 50% vests when it reaches at least $25.00, assuming Jayson Rieger remains in continuous service.

Does this Verrica (VRCA) Form 4 show any insider stock sales or purchases?

No open-market sales or purchases are reported. The filing shows a grant of an employee stock option to CEO Jayson Rieger, categorized as a grant/award acquisition, with no shares bought or sold in the market in this transaction.

When did Verrica (VRCA) shareholders approve the plan amendment for this option grant?

Shareholders approved the amendment to Verrica’s 2018 Equity Incentive Plan on June 5, 2026. The board’s compensation committee had originally approved the option grant on December 23, 2025, conditioned on this shareholder approval, which made the grant effective.

What is Jayson Rieger’s option position in Verrica (VRCA) after this transaction?

After the reported grant, Jayson Rieger holds 512,269 derivative securities representing options on an equal number of Verrica common shares. All of these options relate to this single grant and are held in direct ownership according to the filing details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rieger Jayson

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 W. GAY ST., SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.21	06/05/2026(1)		A		512,269		(2)	12/23/2035	Common Stock	512,269	$0	512,269	D

Explanation of Responses:

1. The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.

2. 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Jayson Rieger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)